Sharemaestro Newsreel

Precision Trading with United Therapeutics Corporation (UTHR) Risk Zones

This article provides a precision trading analysis for United Therapeutics Corporation (UTHR), indicating divergent sentiment across various time horizons and suggesting choppy conditions. It highlights a breakdown in progress with elevated downside risk and offers three institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—along …

KPMG agrees to settle its part of Canopy Growth securities case

KPMG has agreed to a settlement in a securities class action related to its audit of Canopy Growth Corporation. The settlement specifically addresses whether KPMG's auditor's report for the fiscal year ended March 31, 2022, contained a misrepresentation. This agreement applies only for settlement …

ETFs Investing in Cronos Group Inc Stocks

This article lists several ETFs that hold Cronos Group Inc (7CI) stocks, providing details such as market value, weight, issuer, management style, focus, expense ratio, and AUM for each fund. The ETFs mentioned include the ETFMG Alternative Harvest ETF (MJ), Global X Marijuana Life …

Amneal Pharma A earnings beat by $0.07, revenue topped estimates

Amneal Pharma A (NASDAQ: AMRX) reported strong second-quarter results, surpassing analyst estimates with EPS of $0.300 and revenue of $796.2 million. The company also provided optimistic full-year 2026 guidance, expecting EPS between $0.960-$1.060 and revenue between $3.100B-$3.200B. AMRX stock has shown significant growth, increasing …

Form 4 Indivior PLC For: 3 August By Investing.com

This article announces the filing of Form 4 for Indivior PLC on August 3rd. It appears to be a very brief notification from Investing.com, typical of automated financial news updates regarding regulatory filings. The content primarily consists of navigation, advertisements, and market data rather …

ETFs Investing in BioCryst Pharmaceuticals, Inc. Stocks

This article lists various Exchange Traded Funds (ETFs) that hold stocks of BioCryst Pharmaceuticals, Inc. (BCRX). The ETFs are sorted by their market value and provide details such as issuer, management style, expense ratio, assets under management (AUM), and 3-year NAV total return. The …

Understanding Momentum Shifts in (SUPN)

This article analyzes Supernus Pharmaceuticals Inc. (SUPN) using AI models, highlighting a neutral near-term sentiment and potential mid-term weakness. It identifies a breakdown underway, suggesting lower levels and elevated downside risk. The report provides specific institutional trading strategies, including long, breakout, and short positions, …

Lantheus Holdings Inc Revenue Breakdown – SWB:0L8

Lantheus Holdings Inc (SWB:0L8) generated €1.31 billion in revenue last year, with its PYLARIFY segment being the top performer, contributing €842.15 million. The United States was the largest geographical contributor, accounting for €1.24 billion of the total revenue. These figures show a slight increase …

Why Teva Pharmaceutical Stock Surged This Week

Key Points Teva posted its Q2 results this week, reporting an earnings miss even though sales beat expectations. The company's forward guidance didn't deliver big surprises, but it looked solid enough. Investors were bullish on the company's announcement that it will be replacing its …

HUTCHMED’s FRUZAQLA approved or launched in 41 countries

HUTCHMED reported its 2026 interim results, showing total revenue broadly unchanged at $278.3 million and net income of $15.9 million. Oncology product in-market sales increased significantly, with FRUZAQLA global sales reaching $185.4 million due to strong ex-US growth and launches/approvals in 41 countries. The …

Price to earnings forward of Canopy Growth Corporation – DUS:11L

This article provides financial information for Canopy Growth Corporation (DUS:11L) on the Dusseldorf Stock Exchange, specifically focusing on its forward price-to-earnings ratio. It is a data-focused page from TradingView, offering an overview of the company's financials without detailed analysis.

BHC Surges As Bausch Health Crushes Q2 And Lifts 2026 Outlook

Bausch Health Companies Inc. (BHC) saw its stock surge by 13.62% after reporting strong Q2 results, crushing consensus estimates for EPS and revenue, and lifting its 2026 outlook. The company demonstrated its 13th consecutive quarter of revenue and adjusted EBITDA growth, driven by strong …

Why Alkermes (ALKS) Is Down 7.4% After Q2 Profit Drop And New Equity Shelf Filing

Alkermes plc experienced a 7.4% stock drop after reporting a sharp decline in Q2 2026 net income to US$0.501 million, despite a revenue increase to US$496.01 million. The company also filed a US$311.11 million equity shelf registration, signaling a shift from capital returns to …

Viatris to Present at the Bank of America Securities 2026 Healthcare Conference

Viatris Inc. (Nasdaq: VTRS) announced it will present at the Bank of America Securities 2026 Healthcare Conference on Tuesday, May 12, 2026, at 8 a.m. PT / 11 a.m. ET. Investors and the public can listen to the live webcast on the company's investor …

Bausch Health Companies Inc. 2026 Q2 - Results - Earnings Call Presentation (NYSE:BHC)

Bausch Health Companies Inc. has published its 2026 Q2 earnings call presentation. The company reported an EPS of $1.26, beating estimates by $0.25, and revenue of $2.85 billion, surpassing expectations by $192.90 million with a 12.73% year-over-year increase. This presentation is available for investors …

Arrowstreet Capital Limited Partnership Has $8.16 Million Stock Holdings in Siga Technologies Inc. $SIGA

Arrowstreet Capital Limited Partnership significantly increased its stake in Siga Technologies Inc. by 48.9% in the first quarter, now holding 1.53 million shares valued at $8.16 million. Despite this increased institutional interest, analysts have issued a "Sell" rating for SIGA, with shares opening at …

Janus Henderson Group PLC Has $69.26 Million Stock Holdings in Amylyx Pharmaceuticals, Inc. $AMLX

Quantinno Capital Management LP Grows Stock Holdings in Takeda Pharmaceutical Co. $TAK

Anika Therapeutics (ANIK) Stock Fair Value Rises After Q2 Beat And Higher Guidance

Amneal (AMRX) Stock Looks Fairly Valued Following Raised 2026 Guidance

Viatris (VTRS) Stock May Be Cheap Following Its 107% 1 Year Run

PFE5282055 Bond Profile — Key Metrics

This article provides key metrics for the Viatris Inc. (PFE5282055) corporate bond, including its issuer, issue and maturity dates, outstanding amount, face value, and coupon rate. It also offers a brief overview of Viatris Inc.'s business operations and segments. The bond has an issue …

Avoiding Lag: Real-Time Signals in (PBH) Movement

This article provides a real-time analysis of Prestige Consumer Healthcare Inc. (NYSE: PBH) stock movements, highlighting strong near- and mid-term positive sentiment but a weak long-term outlook. It identifies key resistance levels and offers institutional trading strategies including position, momentum breakout, and risk hedging, …

Tilray Brands (TLRY) grants 281,901 RSUs and withholds shares for taxes

Tilray Brands' Chief Strategy Officer, Denise M. Faltischek, was granted 281,901 Restricted Stock Units (RSUs) on July 29, 2026, which will vest in two equal installments on July 29, 2027, and July 29, 2028, contingent on her continued employment. The report also details her …

Supernus Pharmaceuticals (SUPN) awards 2,500 performance share units

Supernus Pharmaceuticals' Sr. VP of IP, CSO Padmanabh P. Bhatt, was awarded 2,500 Performance Share Units on July 29, 2026. These units, which were part of an award from February 19, 2025, vested upon the achievement of individual performance objectives set on May 3, …

Anika Therapeutics Gains 29%, Insider Trades Reap Benefit

This article reports on Anika Therapeutics' significant stock gain of 29%. The rise in stock price has benefited company insiders who engaged in recent trades.

Cronos Group Number of Employees 2026 | Employee Count & Headcount Data

Cronos Group (CRON) had approximately 603 employees worldwide as of March 2026, a 12.9% decline from 2023. The company is actively hiring with 9 active job postings in 2026, though new postings have slowed. Its workforce is concentrated in North America, with Finance and …

Ebola Cases and Deaths Rapidly Mount - RedHill Updates on Opaganib Emergency Outbreak Development

RedHill Biopharma Ltd. provided an update on the development of opaganib for Ebola virus disease (EVD) as confirmed Bundibugyo ebolavirus cases and deaths have substantially increased. The company is in discussions with African health authorities and research institutions regarding the potential use of opaganib, …

USFDA Approves Dr Reddy's Rituximab Biosimilar for US Market

Dr. Reddy's Laboratories has received USFDA approval for its rituximab biosimilar, a version of Rituxan, which expands its global biosimilars portfolio and strengthens its presence in the US market. The biosimilar, already commercialized in various regions including India and Europe, was developed, manufactured, and …

Collegium Pharma shifts focus to ADHD growth with AZSTARYS buy, expecting $865M revenue in 2026.

Collegium Pharmaceutical is transitioning into a central nervous system (CNS) platform company by acquiring the ADHD drug franchise AZSTARYS for $650 million. This strategic move is expected to generate $60–70 million in revenue by 2026 from AZSTARYS and create over $50 million in annual …

Kiniksa Pharmaceuticals International (KNSA) After Raised 2026 Guidance And Strong Q2 Results Looks Fully Valued

Tilray Brands (NASDAQ:TLRY) Rating Increased to Strong-Buy at TD Securities

TD Securities has upgraded Tilray Brands (NASDAQ:TLRY) to a "strong-buy" rating, despite mixed analyst sentiment and recent downgrades from other firms. The cannabis company's shares rose 8.1% on the news but remain significantly below their 52-week high, with ongoing profitability concerns highlighted by a …

Elanco Releases 2025 Impact Report, Demonstrating How Animal Health Helps Meet Society's Growing Needs

Elanco Animal Health Inc. has released its "2025 Impact Report," detailing how the company's focus on innovation and purpose addresses societal challenges related to animal health

BHC Soars As Bausch Health Earnings Beat Triggers Repricing

Bausch Health Companies Inc. (BHC) surged by 13.62% following stronger-than-expected Q2 earnings, beating consensus on both EPS and revenue, marking its 13th consecutive quarter of revenue and adjusted EBITDA growth. The company also reported strong operating cash flow and reduced net debt, leading to …

Janus Henderson Group PLC Has $145.08 Million Position in Teva Pharmaceutical Industries Ltd. $TEVA

Janus Henderson Group PLC increased its stake in Teva Pharmaceutical Industries Ltd. by 1.5% in Q1, holding 4.82 million shares valued at $145.08 million. Institutional investors collectively own 54.05% of Teva, and analysts maintain a "Moderate Buy" rating with an average price target of …

Indivior Q2 2026 slides: SUBLOCADE drives 111% EBITDA surge

Indivior PLC reported strong Q2 2026 financial results, with adjusted EBITDA surging 111% driven by its opioid use disorder treatment, SUBLOCADE. Despite exceeding analyst expectations, the company's stock experienced a slight decline, likely due to investor caution regarding its proposed merger with Supernus Pharmaceuticals. …